289483-92-7

Basic information

• Product Name: 6-Aminopyridine-3-sulfonyl chloride
• Synonyms: 6-Aminopyridine-3-sulfonyl chloride;6-Amino-3-pyridinesulfonyl Chloride
• CAS NO: 289483-92-7
• Molecular Formula: C₅H₅ClN₂O₂S
• Molecular Weight: 193
• Mol File: 289483-92-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-Aminopyridine-3-sulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Aminopyridine-3-sulfonyl chloride(289483-92-7)
• EPA Substance Registry System: 6-Aminopyridine-3-sulfonyl chloride(289483-92-7)

Safety Data

• Hazardous Substances Data: 289483-92-7(Hazardous Substances Data)

Usage

Description

6-Aminopyridine-3-sulfonyl chloride is an organic compound with the molecular formula C5H5ClN2O2S. It is a derivative of aminopyridine, featuring a sulfonyl chloride group attached to the 3-position of the pyridine ring. 6-Aminopyridine-3-sulfonyl chloride is known for its reactivity and is commonly utilized in the synthesis of various pharmaceuticals and bioactive molecules.

Uses

Used in Pharmaceutical Industry:
6-Aminopyridine-3-sulfonyl chloride is used as a key intermediate in the synthesis of potent and selective covalent inhibitors for transglutaminase 2. These inhibitors are crucial in the discovery and development of therapeutic agents for Huntington's Disease, a neurodegenerative disorder.
Used in Research and Development:
In the field of research and development, 6-Aminopyridine-3-sulfonyl chloride serves as a valuable building block for the creation of novel compounds with potential applications in various therapeutic areas. Its reactivity allows for the formation of diverse chemical structures, facilitating the exploration of structure-activity relationships and the optimization of drug candidates.
Used in Chemical Synthesis:
6-Aminopyridine-3-sulfonyl chloride is also employed as a reagent in various chemical synthesis processes, particularly in the preparation of sulfonamide derivatives and other sulfur-containing compounds. Its versatility in forming covalent bonds with different molecular entities makes it a valuable asset in the synthesis of complex organic molecules.

Upstream product

• 504-29-0 2-aminopyridine 

Downstream Products

• 477739-45-0 C₂₃H₂₃FN₄O₅S₂ 
• 1306722-80-4 4-(6-acryloylaminopyridine-3-sulfonyl)piperazine-1-carboxylic acid benzyl ester 
• 1361224-54-5 2-(4-((2R)-4-((6-amino-3-pyridinyl)sulphonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1361224-53-4 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulphonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1361224-48-7 2-(4-(4-((6-amino-3-pyridinyl)sulphonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 

Relevant articles and documents

SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS

The present invention relates to a class of sulfonamide-substituted cyanopyrrolidines of Formula (Ia) and (Ib) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction: (Formulae (Ia), (Ib)).

HEPATITIS B VIRAL ASSEMBLY EFFECTORS

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease

Tissue transglutaminase 2 (TG2) is a multifunctional protein primarily known for its calcium-dependent enzymatic protein cross-linking activity via isopeptide bond formation between glutamine and lysine residues. TG2 overexpression and activity have been found to be associated with Huntington's disease (HD); specifically, TG2 is up-regulated in the brains of HD patients and in animal models of the disease. Interestingly, genetic deletion of TG2 in two different HD mouse models, R6/1 and R6/2, results in improved phenotypes including a reduction in neuronal death and prolonged survival. Starting with phenylacrylamide screening hit 7d, we describe the SAR of this series leading to potent and selective TG2 inhibitors. The suitability of the compounds as in vitro tools to elucidate the biology of TG2 was demonstrated through mode of inhibition studies, characterization of druglike properties, and inhibition profiles in a cell lysate assay.